CVS Health Q2 2021 Earnings Report
Key Takeaways
CVS Health announced strong Q2 2021 results with total revenues increasing to $72.6 billion, up 11.1% compared to the prior year. The company raised its full year EPS and cash flow from operations guidance.
Total revenues increased to $72.6 billion, up 11.1% compared to prior year
GAAP diluted EPS of $2.10 and Adjusted EPS of $2.42
Administered more than 6 million COVID-19 tests and nearly 17 million COVID-19 vaccines nationwide in the second quarter
Launched new Clinical Trial Services business to drive greater access to clinical trials
CVS Health
CVS Health
CVS Health Revenue by Segment
Forward Guidance
The Company raised its full year 2021 GAAP diluted EPS guidance range to $6.35 to $6.45 from $6.24 to $6.36 and its full year 2021 Adjusted EPS guidance range to $7.70 to $7.80 from $7.56 to $7.68 and raised its full year 2021 cash flow from operations guidance range to $12.5 billion to $13.0 billion from $12.0 billion to $12.5 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income